TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03385057
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
Study: NCT00654329
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl, nasal transmucosal, 2 micrograms/kilogram
Study: NCT02206087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversal of heparin-induced anticoagulation
Study: NCT02206087
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00508859
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02459236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03749148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00004097
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00349245
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01631617
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
Study: NCT03687242
Drug: SPR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label SPR001
Study: NCT02489318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo orally once daily in each 28 day treatment cycles.
Study: NCT02489318
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study: NCT00726388
Drug: DIC075V (intravenous diclofenac sodium)
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: multiple doses up to 5 days
Study: NCT04312971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
Study: NCT04312971
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
Study: NCT02435381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment only
Study: NCT04500808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo from Day 1 up to Day 13.
Study: NCT02110225
Drug: rhNGF 60 µg/ml eye drops solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Study: NCT02110225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Study: NCT02176018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01116440
Drug: BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
Study: NCT01116440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
Study: NCT00666835
Drug: ERYPO®, Janssen-Cilag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for i.v. injection
Study: NCT01842399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x/day orally
Study: NCT04127019
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide chemotherapy (injection)
Study: NCT03086070
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
Study: NCT01552668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive Placebo twice daily
Study: NCT03689153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo intravenously.
Study: NCT02862431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT00003402
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00220116
Drug: Capecitabine, Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02519452
Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study: NCT04175808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT00291642
Drug: Placebo drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use
Study: NCT03134976
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
Study: NCT03759028
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study: NCT03759028
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study: NCT02997228
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02997228
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02194777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02842125
Drug: Ad-P53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Study: NCT02810483
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days.
Study: NCT00082706
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
Study: NCT01325818
Drug: pravastatin, rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day
Study: NCT00427297
Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line regimen
Study: NCT03336073
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
Study: NCT00585208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for ramelteon 8mg daily
Study: NCT04045522
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
Study: NCT02216149
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
Study: NCT01562483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to the Namisol arm.
Study: NCT02768077
Drug: Melatonin(Circadin®)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02768077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01329185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule twice a day for 14 days prior to transplant date
Study: NCT03007693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ- 61393215 matching placebo for 7 days.
Study: NCT04214691
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study: NCT00549042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04043806
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study: NCT04679597
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison of two treatments
Study: NCT02611921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
Study: NCT03069014
Drug: 400mg LM11A-31-BHS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
Study: NCT03069014
Drug: 800mg LM11A-31-BHS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
Study: NCT03069014
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
Study: NCT00621946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Matching Escitalopram
Study: NCT00721825
Drug: Neuroaid matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroaid matched placebo 4 capsules three times per day during one month
Study: NCT02021292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral tablet, to be taken once daily.
Study: NCT04501978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion
Study: NCT02788045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
Study: NCT01229527
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
Study: NCT01229527
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
Study: NCT03955445
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNP023 capsules
Study: NCT02828592
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
Study: NCT02828592
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
Study: NCT04167085
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline, 100 mg twice a day for 2 months
Study: NCT03036124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching dapagliflozin 10 mg or 5 mg.
Study: NCT01283971
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10-25 mg weekly.
Study: NCT00584376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
Study: NCT01766323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
Study: NCT02177435
Drug: Telmisartan/Hydrochlorothiazide
Normalized name: telmisartan/hydrochlorothiazide 80 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01038674
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Study: NCT03044093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group that will only get Misoprostol
Study: NCT04551703
Drug: Adrenaline saline irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
Study: NCT00432575
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02722122
Drug: AIR DNase™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00730210
Drug: a: PTH (1-84)
Approvals — FDA: no, EMA: no, PMDA: no
Description: preotact 100 microgram subcutaneous a day in 6 months
Study: NCT00730210
Drug: b:placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microgram placebo subcutaneous a day for 6 months
Study: NCT03946514
Drug: losartan/hydrochlorothiazide
Normalized name: losartan/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
Study: NCT03946514
Drug: amlodipine/hydrochlorothiazide
Normalized name: AMLODIPINE/HYDROCHLOROTHIAZIDE/VALSARTAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
Study: NCT02979613
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet administered orally once daily
Study: NCT02979613
Drug: TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02979613
Drug: TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT03303625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
Study: NCT01613807
Drug: Insulin, Long-Acting and Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Study: NCT00672763
Drug: Colecalciferol D3 (Vigantol Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses).
Study: NCT00672763
Drug: Medium chain triglycerides
Normalized name: medium chain triglycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)
Study: NCT01136746
Drug: Human regular insulin
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
Study: NCT02596399
Drug: DSTA4637S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive DSTA4637S intravenously on Day 1.
Study: NCT02596399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
Study: NCT02515656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518583
Drug: Pegylated Liposomal Doxorubicin (Doxil)
Normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
Study: NCT02422641
Drug: High-dose Methotrexate (8 gm/m2; HD-MTX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
Study: NCT02435797
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
Study: NCT02603861
Drug: LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3154207 administered orally.
Study: NCT02603861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally.
Study: NCT01543906
Drug: QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral QLT091001 administered once daily for 7 days
Study: NCT00405912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive drug) given 3 times per day
Study: NCT01965145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution administered subcutaneously
Study: NCT01191697
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken orally on days 1-14 of each cycle beginning cycle 2
Study: NCT04491006
Drug: ATH-1017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Study: NCT04491006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Study: NCT00598286
Drug: [18F]FMPEP-d2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04838145
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to treatment with placebo
Study: NCT02503306
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablets Route of administration: oral